A blood test showed a signal in depression. The field has heard this before.

Depression is diagnosed with checklists. A doctor asks if you've lost interest in things, felt hopeless, had thoughts of failure — and if enough answers cross a threshold, you qualify. There is no blood test. No imaging. No molecular signature. The condition that affects nearly one in five US adults is diagnosed the same way it was fifty years ago.

A study published in The Journals of Gerontology, Series A offers a potential clue toward something more concrete. Researchers found that a specialized type of blood test — one that measures how much the DNA in a specific kind of immune cell has chemically aged — showed a measurable link to depression symptoms in 440 women. The test picked up on anhedonia, hopelessness, and feelings of failure. It did not predict who would develop depression. It correlated with who already had it.

The distinction matters. News-Medical reported that the research team used a monocyte-specific epigenetic clock — a blood test that reads chemical modifications on DNA in monocytes, a type of immune cell. Epigenetic clocks are a way of measuring biological aging by tracking these modifications, which accumulate on DNA over time like marks on a clock face. Previous attempts to link broader epigenetic clocks — measuring many cell types at once — to depression found nothing. This one found something.

"Monocytes are immune cells that circulate in the blood and can enter the brain," said lead researcher Perez, according to ScienceDaily. "Aging in these cells was strongly associated with non-somatic symptoms of depression." Non-somatic means the psychological kind — anhedonia and hopelessness rather than, say, fatigue or changes in appetite.

The study drew from the Women's Interagency HIV Study (WIHS), a long-running US cohort that has tracked women with and without HIV since the 1990s. Of the 440 participants, 261 were living with HIV and 179 were not. The cohort was originally assembled to study HIV outcomes, but its detailed medical records made it useful for studying immune aging and mood.

That monocyte-specific clocks performed better than broad ones is the finding that most interests researchers in the field. When a test measuring multiple cell types showed no signal, but a test targeting only monocytes did, it suggests the relevant biology is concentrated in one cell type — not scattered across the bloodstream. The result needs replication, but it offers a specific hypothesis: something about how monocytes age is entangled with how depression manifests, at least in this population.

Depression biomarker research has a history of promising signals that evaporate in later studies. The field is crowded with findings that held in one cohort and failed in the next. The authors themselves caution that more research is needed before the findings could inform how depression is measured or treated. Perez noted that the study measured current symptoms, not future onset — a caveat the researchers consider central to how the work should be interpreted.

The study also does not address whether the monocyte aging signal is specific to women in this age range, or to women with the demographic profile of the WIHS cohort. WIHS participants are predominantly middle-aged women with either HIV or comparable risk factors. Generalizing to men, to younger populations, or to people without HIV-related immune activation would require separate studies.

What the research does not claim is a predictive test. ScienceDaily ran the study under the headline "this simple blood test might detect depression before symptoms appear" but the study measured people who already had symptoms. There is no evidence yet that the clock identifies people before depression shows up in their answers to a doctor's checklist.

That said, the specificity signal is real. If monocytes are involved in depression biology — circulating, potentially entering the brain, showing age-related changes that track with mood — that is a thread worth pulling. Whether it leads somewhere that matters for diagnosis, treatment, or understanding of the disease itself is still an open question.

The research was published in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences.